How to deal with Erdafitinib resistance?

Resistance to targeted drugs such as Erdafitinib (Erdafitinib) is one of the important challenges in the field of cancer treatment. The development of drug resistance may result in the loss of effective cancer control by drugs and therefore requires strategies to deal with it. Here are some possible ways to deal with erdafitinib resistance:

1.Perform genetic testing: When a patient shows resistance to erdafitinib, it is crucial to undergo genetic testing. This can help determine whether mutations or other genetic changes to drug targets have occurred, guiding subsequent treatment choices.

2.Switching treatment options: Once drug resistance is confirmed, doctors may consider switching to other treatment options, such as trying different targeted drugs or immunotherapy. The choice of new treatment options often depends on the individual patient's condition, tumor characteristics, and the latest clinical research results.

3.Combination therapy: Combination of multiple drugs may be a strategy to enhance treatment efficacy and slow the development of drug resistance. Combining targeted drugs, chemotherapy drugs, or immunotherapy may provide a more comprehensive treatment effect.

4.Individualized treatment strategies: Individualized treatment strategies need to be developed to deal with drug resistance. Understanding the patient's genotype, molecular pathology, tumor biological characteristics and other information can help doctors better choose appropriate treatment options.

5.Participation in clinical trials: In some cases, patients may consider participating in clinical trials, especially for new treatment options targeting drug resistance. Clinical trials provide patients with the opportunity to try new treatments and help advance medical research.

6.Treatment Intermittent: In some cases, doctors may consider using a treatment intermittent approach, which is to stop drug treatment for a period of time in order to resensitize the tumor's response to the drug. Such strategies need to be carefully considered and determined by the physician based on the patient's specific circumstances.

7.Comprehensive treatment team: Tackling drug resistance usually requires the collaboration of a comprehensive treatment team, including doctors, oncologists, geneticists, clinical trial researchers, etc. They work together to develop a treatment plan and monitor and make adjustments during treatment.

8.Supportive treatment: In the process of treating drug resistance, the patient's quality of life also needs to be paid attention to. Supportive care, including pain management, psychological support, nutritional support, etc., can help patients better cope with various challenges during treatment.

It should be noted that the development of drug resistance is a complex and multifactorial process, so strategies for dealing with drug resistance should be individualized and carried out under close monitoring. In addition, scientific research and clinical practice continue to evolve, potentially leading to new treatment strategies. Therefore, patients and doctors should maintain open communication and regularly evaluate treatment options so that timely adjustments can be made and the best medical care can be provided. For the latest information and treatment options, consult a medical professional or refer to the latest medical literature.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.